ICU Equipment in Washington

BrainSpace develops automated cerebrospinal fluid (CSF) management systems for acute care settings. The company's flagship product, the Intellidrop, automates external ventricular drainage (EVD) and lumbar drain management at the bedside, replacing labor-intensive manual monitoring with robotic precision and closed-loop automation. The Intellidrop features a wearable transducer that eliminates the need for manual leveling or zeroing, reducing nursing workload while improving patient experience and clinical outcomes. The system combines continuous sensing and gravity-based drainage principles trusted by neurosurgeons, enabling single-drop drainage control with personalized pressure or volume targets for each patient. The device generates high-frequency multimodal data that can be autonomously annotated in real-time, supporting research and AI training without manual data cleaning. BrainSpace's technology addresses CSF management for acute conditions including traumatic brain injury (TBI), hemorrhagic stroke, meningitis, post-neurosurgical care, and diagnostic evaluation for normal pressure hydrocephalus (NPH). The company targets ICU settings where improved automation is expected to support patient mobilization, reduce length of stay, alleviate nursing staffing challenges, and expand access to critical CSF management.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in photodisinfection (antimicrobial photodynamic therapy) technologies for infection prevention and treatment. The company's patented platform uses non-thermal laser light activation with photosensitive agents to destroy bacteria, viruses, yeasts, fungi, and associated virulence factors within minutes—without generating antimicrobial resistance. The lead product, Steriwave, is a rapid nasal decolonization therapy that eliminates broad-spectrum pathogens including methicillin-resistant Staphylococcus aureus (MRSA), Candida auris, and SARS-CoV-2 from the nasal cavity, significantly reducing healthcare-associated infections (HAIs) and surgical site infections (SSIs). Clinical evidence from major Canadian hospitals demonstrates up to 84% reduction in postoperative infection rates and 39.5% pneumonia reduction in ICU settings. Photodisinfection offers advantages over traditional antibiotics including immediate pathogen destruction, potent anti-inflammatory effects, and safety for patient outcomes. The company maintains a pipeline of investigational products addressing chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection to prevent ventilator-associated pneumonia, and topical antiviral therapies for upper respiratory tract infections. Ondine's technology platform is designed for straightforward clinical adoption with minimal workflow disruption and no complex compliance barriers. Note: Products are not currently for sale in the United States. The company operates as a specialized biomedical device and therapeutic solutions provider focused on addressing antimicrobial resistance through innovative light-activated infection control mechanisms.